[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100628977":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":13,"locations":7,"responsibleParty":22,"collaborators":7,"id":24,"slug":7,"hasResults":25,"nctId":26,"briefTitle":27,"officialTitle":28,"acronym":7,"eligibilityCriteria":29,"healthyVolunteers":25,"sex":30,"minAge":31,"maxAge":7,"enrollmentInfo":32,"targetDuration":7,"studyType":35,"phases":7,"briefSummary":36,"conditions":37,"keywords":7,"overallStatus":39,"whyStopped":7,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":7},{"fullName":5,"class":6},"Duke University","OTHER",null,[9],{"name":10,"affiliation":11,"role":12},"Laura Alder, MD","Duke Health","PRINCIPAL_INVESTIGATOR",[14,18],{"name":10,"role":15,"phone":16,"phoneExt":7,"email":17},"CONTACT","+1 919 862 5400","laura.alder@duke.edu",{"name":19,"role":15,"phone":20,"phoneExt":7,"email":21},"Daniel Hess, MD, PhD","+1 919 684 8111","daniel.hess@duke.edu",{"type":23,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100628977",false,"NCT07468656","SCLC Tarlatamab Blood Collection","Analysis of Blood Samples in Small Cell Lung Cancer Patients Treated With Tarlatamab","Inclusion Criteria:\n\n* Pathologically documented small cell lung cancer (SCLC) or neuroendocrine tumor\n* Appropriate candidate for treatment with tarlatamab based on investigator discretion\n* Age \\> 18 years\n* Signed written informed consent including HIPAA according to institutional guidelines\n\nExclusion Criteria:\n\n* Does not meet all inclusion criteria","ALL","18 Years",{"count":33,"type":34},25,"ESTIMATED","OBSERVATIONAL","The overall objective of this project is to prospectively collect blood samples throughout treatment with tarlatamab in patients with small cell lung cancer (SCLC). These samples will then be analyzed through a variety of assays to better characterize tarlatamab in the real-world setting.\n\nThe investigators will prospectively collect blood samples from 25 patients on days 1, 8, and 15 of tarlatamab treatment, as well as after each interval scan for disease monitoring. The investigators will also collect patient data including demographics and baseline characteristics, primary diagnosis, treatment history, and disease monitoring and progression.",[38],"Small-cell Lung Cancer","NOT_YET_RECRUITING","2026-06-02",{"date":42,"type":43},"2026-06-03","ACTUAL",{"date":45,"type":34},"2026-07",{"date":47,"type":34},"2028-12",{"name":5,"class":6}]